ReviewFrontiers in cellular and infection microbiology2023
Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer.
Review in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 41 citations in OpenAlex.
- Cancer and Hypertension: Shared Mechanisms, Treatment Interactions, and Clinical Management.Cancer medicine · 2026Review
- Protective Effects of Double-layered Multinucleated Microcapsules Containing Bifidobacterium adolescentis FS2-3 Against Enteritis Mediated by Different Pathogens.Probiotics and antimicrobial proteins · 2026Article
- Longitudinal frailty trajectories and risk of incident chronic liver disease among middle-aged and older Chinese adults: the mediating role of depressive symptoms.Research square · 2026Article
- Article
- Deubiquitinating Enzymes as Therapeutic Candidates in Hepatocellular Carcinoma and Other Liver Disease.International journal of molecular sciences · 2026Review
- Global research on the crosstalk between microbiota - intratumoral microorganisms and liver cancer: a visualization analysis.Infectious agents and cancer · 2026Article
- Molecular and mechanistic insights into the gut-liver axis inInfection and immunity · 2026Review
- [Research progress on the mechanisms and optimization strategies of mesenchymal stem cell-derived exosomes in the treatment of liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Exploratory Analysis of Gut Microbiome and Metabolic Profile Changes Following Lenvatinib and Anti-PD-1 Combination Therapy in Liver Cancer.Metabolites · 2026Article
- Gut microbial signatures of advanced hepatocellular carcinoma and their potential diagnostic value.Frontiers in microbiology · 2026Article
- From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma.Frontiers in cellular and infection microbiology · 2026Review
- Natural polysaccharides as immunometabolic modulators in metabolic diseases: mechanisms and translational challenges.Frontiers in immunology · 2026Review
- Adjuvant therapeutic effects and mechanisms of Yinchenhao decoction in obstructive jaundice: a narrative review.Frontiers in pharmacology · 2026Review
- Multi-target modulation of traditional Chinese medicine based on the liver-gut axis: a new therapeutic strategy for NAFLD.American journal of translational research · 2026Review
- Gut Microbiota-induced Long Non-coding RNA Snhg9 Regulates the Development of Human Malignant Tumors.Current molecular medicine · 2026Review
- Total flavonoids of Potentilla discolor alleviate type 2 diabetes by regulating gut microbiota and endogenous metabolites.Frontiers in microbiology · 2026Article
- The Therapeutic Effect and Mechanism ofJournal of microbiology and biotechnology · 2025Article
- Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-κB Inhibition.Journal of experimental & clinical cancer research : CR · 2025Article
- The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Metagenomic next-generation sequencing reveals respiratory flora distribution in COVID-19.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver is a vital metabolism and detoxification organ of human body, which is involved in the biotransformation and metabolism of the organism. Hepatitis - cirrhosis - liver cancer are significant and common part of liver diseases. The pathogenesis of liver diseases is generally as followed: inflammation and other pathogenic factors cause persistent damage to the liver, leading to the activation of hepatic stellate cells (HSCs) and excessive deposition of extracellular matrix. Patients with chronic hepatitis have a high risk of developing into liver fibrosis, cirrhosis, and even life-threatening liver cancer, which poses a great threat to public health.As the first organ to come into contact with blood from the gut, the liver is profoundly affected by the intestinal flora and its metabolites, with leaky gut and flora imbalance being the triggers of the liver's pathological response. So far, no one has reviewed the role of intestinal flora in this process from the perspective of the progression of hepatitis-cirrhosis-liver cancer and this article reviews the evidence supporting the effect of intestinal flora in the progression of liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.